Details of the Drug Combinations

General Information of This Drug (ID: DMICDLV)

Drug Name

Lorlatinib DMICDLV

Synonyms

Loratinib; UNII-OSP71S83EU; Lorlatinib,PF-06463922; OSP71S83EU; lorlantinib; 4clj; 4cli; Lorlatinib [USAN:INN]; Lorlatinib (JAN/USAN/INN); PF06463922(Lorlatinib); GTPL7476; SCHEMBL15261807; EX-A828; MolPort-035-789-724; KS-00000T6C; 2641AH; ZINC98208524; s7536; MFCD28144520; BDBM50018830; AKOS027250753; DB12130; CS-39

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Approved	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Arry-162 + Lorlatinib	DCATITY	Arry-162	Lung Cancer	[2]
Crizotinib + Lorlatinib	DC59Z33	Crizotinib	Lung Cancer	[2]
Brigatinib + Lorlatinib	DC8OILK	Brigatinib	Lung Non-Squamous Non-Small Cell Carcinoma	[3]
------------------------------------------------------------------------------------

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	ClinicalTrials.gov (NCT04292119) Lorlatinib Combinations in Lung Cancer
3	ClinicalTrials.gov (NCT03737994) Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer